__timestamp | Arrowhead Pharmaceuticals, Inc. | HUTCHMED (China) Limited |
---|---|---|
Wednesday, January 1, 2014 | 24419536 | 26684000 |
Thursday, January 1, 2015 | 34718089 | 29829000 |
Friday, January 1, 2016 | 40998209 | 39578000 |
Sunday, January 1, 2017 | 32022880 | 43277000 |
Monday, January 1, 2018 | 19110051 | 48645000 |
Tuesday, January 1, 2019 | 26556257 | 52934000 |
Wednesday, January 1, 2020 | 52275890 | 61349000 |
Friday, January 1, 2021 | 80981000 | 127125000 |
Saturday, January 1, 2022 | 124431000 | 136106000 |
Sunday, January 1, 2023 | 90932000 | 133175999 |
Monday, January 1, 2024 | 98761000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc., from 2014 to 2023. Over this period, HUTCHMED consistently outpaced Arrowhead in SG&A spending, peaking in 2022 with a 10% higher expenditure. Notably, HUTCHMED's expenses surged by approximately 410% from 2014 to 2022, reflecting its aggressive expansion strategy. In contrast, Arrowhead's SG&A expenses grew by about 410% over the same period, indicating a more measured approach. The data for 2024 is incomplete, highlighting the need for ongoing analysis. This comparison underscores the strategic financial decisions shaping the future of these pharmaceutical giants.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and HUTCHMED (China) Limited
Comparing SG&A Expenses: argenx SE vs HUTCHMED (China) Limited Trends and Insights
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs HUTCHMED (China) Limited
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Arrowhead Pharmaceuticals, Inc.
Viatris Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Grifols, S.A. and Arrowhead Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited
Breaking Down SG&A Expenses: Corcept Therapeutics Incorporated vs Arrowhead Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: ADMA Biologics, Inc. vs HUTCHMED (China) Limited
HUTCHMED (China) Limited and MannKind Corporation: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing HUTCHMED (China) Limited and MiMedx Group, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and MannKind Corporation